Vision-DMD Project

Project aiming to advance clinical development of orphan drug Vamorolone for treatment of DMD.

[Vision-DMD Project @Vision_DMD]

The VISION-DMD project is proud to announce ' Santhera have Received Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy' Read the press release here CHMP-press-release.pdf (https://t.co/h1plFYS3XP)

[Vision-DMD Project @Vision_DMD]

VISION-DMD rare disease day final project newsletter - https://t.co/jziOxqVkx8

[Duchenne Data Foundation @DuchenneDF]

Eric Hoffman, Suzanne Gaglianone @smgag19 from @ReveraGen and Ritchie Head from Ceratium share their experience on what Patient Organizations can do to have data return from clinical trials
#DPA2021 #duchenne

[Duchenne Data Foundation @DuchenneDF]

''Patients want their data returned after a clinical trial'' Ritchie Head from Ceratium, is talking about the patients preferences on the return of their data following a clinical trial.
#DPA2021 #duchenne

[World Duchenne Organization @worldduchenne]

Throughout the study, Vamorolone:
→ Showed sustained efficacy across multiple endpoints over 48 weeks
→ Good safety and tolerability profile was confirmed
More about the topline results from the @Vision_DMD study 👇
https://t.co/gowNxkSp7F

[Vision-DMD Project @Vision_DMD]

Latest news and events from VISION-DMD - https://t.co/439IwNcPo9

[Vision-DMD Project @Vision_DMD]

#Vamorolone #Venturephilanthropy #DMD

[Vision-DMD Project @Vision_DMD]

Come and visit us at the WODC 21- stand 79! #WODC #Raredisease #DMD @jwmdrc @worldduchenne

[World Duchenne Organization @worldduchenne]

💬 What is the patient perspective on returning individual clinical trial data back to participants after a trial has ended?
Help @Vision_DMD answer this question. Please complete this short 4-minute survey 👇
https://t.co/L8cf9isW8g
#Duchenne #ClinicalTrial #HealthData

[World Duchenne Organization @worldduchenne]

🚨 Important notice on 'stem cell therapy for Duchenne'. Please RT!
→ Currently, there are no approved stem cell therapies for #Duchenne
→ You NEVER pay for a clinical trial
→ If a ‘trial’ is not on https://t.co/9Ypo7B9Ogz, it is not a legitimate trial
https://t.co/gF0RmJVXyF

[Vision-DMD Project @Vision_DMD]

The power of collaboration: Positive results in VISION DMD study funded by #Horizon2020, #DMD #PatientGroups and US Gov – we are now entering the final phase towards Market Authorisation @santhera @ReveraGen @CORDIS_EU @EUScienceInnov #WDAD2021

[Vision-DMD Project @Vision_DMD]

Read our latest project news! - https://t.co/dTiAmuF2Bf

[Vision-DMD Project @Vision_DMD]

Today, @Santhera and @ReveraGen announce topline results with Vamorolone in pivotal VISION-DMD study. Santhera will hold a conference call / webcast today at 16:00 CEST, 15:00 BST, 10:00 EDT. Details: https://t.co/cPVdZS2GD9

[Vision-DMD Project @Vision_DMD]

Latest news from the VISION-DMD project - https://t.co/2bCmlwfGlO

[Vision-DMD Project @Vision_DMD]

@DuchenneUK Glad to have you!

[Hélène Le Borgne @HeleneLBorgne]

Thanks #EUfunded @EJPRareDiseases research co-fund for advertising this White Paper of #EUfunded research @Vision_DMD project: returning individual clinical trial results back to patients - important not only for rare disease patients ! @EU_H2020 #ResearchImpactEU

[Vision-DMD Project @Vision_DMD]

📍 New VISION-DMD White Paper: Returning Individual Clinical Trial Results Back To Patients. It focuses on addressing the ethical and technical challenges, using the vamorolone clinical trial experience.
#clinicaltrials #scicomm #medtech
https://t.co/XfOMhKr1mf

[Vision-DMD Project @Vision_DMD]

Read the latest newsletter here - https://t.co/IZLlRZQLVA